Marvin BurnsRadiation Oncology/TherapyNew technology spurs investment in brachytherapyThe U.S. market for brachytherapy products should exceed $1 billion in the next five years, driven by the introduction of new products that allow accelerated treatment for cancer patients after surgery. The worldwide market could grow even more rapidly, according to this analysis from market research firm Bio-Tech Systems.April 22, 2009Nuclear MedicineNew growth for diagnostic radiopharmaceuticalsBased on the number of new products in the pipeline and the amount of venture capital being invested, the future looks promising for radiopharmaceuticals. Current research efforts include novel approaches to imaging myocardial infarction, congestive heart failure, in vivo infection imaging, and new molecular imaging methodologies for oncology.November 8, 2006Nuclear MedicineNew promise for therapeutic radiopharmaceuticalsA surge in research activity is expanding the applications for therapeutic radiopharmaceuticals, which are employing more sophisticated targeting methodologies and more appropriate therapeutic isotopes for the tumors being treated. These new agents will reduce treatment time and accelerate recovery for many patients.June 1, 2006Nuclear MedicineCan SPECT/CT revitalize nuclear medicine?SPECT/CT has been introduced recently with the expectation that it will emulate PET/CT's success as a hybrid imaging modality. Proponents are confident that the addition of CT will provide a new springboard for SPECT in nuclear cardiology as well as other functional studies, revitalizing traditional nuclear medicine.July 6, 2005Page 1 of 1Top StoriesMRIDeep learning plus MRI predicts likelihood of postpartum hemorrhageAround the world, postpartum hemorrhage is one of the primary causes of complications and fatalities among women.Womens ImagingPersonal tragedies spur unity behind bill for diagnostic breast careMRIFDA cites MRI study in new requirements for COVID-19 manufacturersMolecular ImagingSNMMI: Consider radiation safety when adding F-18 MPI to the radiation oncology suiteCTACS: Half of cancer mortality due to modifiable risk factors
